Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer, Nature, vol.448, issue.7153, pp.561-567, 2007. ,
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer, N Engl J Med, vol.368, issue.25, pp.2385-94, 2013. ,
Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial, Lancet, vol.390, pp.29-39, 2017. ,
Alectinib versus Crizotinib in untreated ALK-positive non-small-cell lung Cancer, N Engl J Med, vol.377, issue.9, pp.829-867, 2017. ,
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study, Lancet, vol.389, pp.917-946, 2017. ,
Brigatinib versus Crizotinib in ALK-positive non-small-cell lung cancer, N Engl J Med, vol.379, issue.21, pp.2027-2066, 2018. ,
An orally available small-molecule inhibitor of c-met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms, Cancer Res, vol.67, issue.9, pp.4408-4425, 2007. ,
Systemic therapy for stage IV non-small-cell lung cancer: American society of clinical oncology clinical practice guideline update, J Clin Oncol, vol.35, issue.30, pp.3484-515, 2017. ,
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study, Lancet Oncol, vol.19, pp.1654-67, 2018. ,
Brigatinib in Crizotinib-refractory ALK+ non-small cell lung Cancer: 2-year follow-up on systemic and intracranial outcomes in the phase 2 ALTA trial, J Thorac Oncol, 2019. ,
Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: an expert consensus, Lung Cancer, vol.87, issue.2, pp.89-95, 2015. ,
Esophagitis: a novel adverse event of crizotinib in a patient with ALK-positive non-small-cell lung cancer, J Thorac Oncol, vol.8, issue.3, pp.23-27, 2013. ,
Natural history and factors associated with overall survival in stage IV ALKrearranged non-small cell lung Cancer, J Thorac Oncol, vol.14, issue.4, pp.691-700, 2019. ,
Extended survival and prognostic factors for patients with ALKrearranged non-small-cell lung Cancer and brain metastasis, J Clin Oncol, vol.34, issue.2, pp.123-132, 2016. ,
Renal cyst formation in patients treated with crizotinib for non-small cell lung cancerincidence, radiological features and clinical characteristics, Lung Cancer, vol.106, pp.33-39, 2017. ,
Crizotinib-induced pancreatic pseudocyst: a novel adverse event, BMJ Case Rep, p.2015211556, 2015. ,
Osteonecrosis of the jaw in the era of targeted therapy and immunotherapy in oncology, J Korean Assoc Oral Maxillofac Surg, vol.45, issue.1, pp.3-8, 2019. ,
From osteoclast differentiation to osteonecrosis of the jaw: molecular and clinical insights, Int J Mol Sci, vol.20, issue.19, p.4925, 2019. ,